The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Rintega® Improves Survival in Patients with Glioblastoma Multiforme (07-1-2015)

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May... Continue Reading

Better Outcomes in Oral Cancer with Surgery to Remove Lymph Nodes in Neck before Cancer Spreads (06-30-2015)

In early squamous-cell oral cancer, surgery to remove lymph nodes in the neck before cancer spreads may result in better outcomes. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago,... Continue Reading

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma (06-29-2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

Aetna Provides Coverage for Biodesix’ VeriStrat Test (06-25-2015)

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic test on June 5th, stating the test is medically... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (06-24-2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (06-23-2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University... Continue Reading

BCM Study Findings Show That a Mother’s Diet Before Pregnancy May Affect Her Child’s Lifelong Cancer Risk (06-17-2015)

A collaborative team of international researchers led by Dr. Robert Waterland, PhD, associate professor of pediatrics and nutrition at Baylor College of Medicine (BCM) and the USDA/ARS Children’s Nutrition Research Center at Baylor and Texas Children’s... Continue Reading

Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer (06-15-2015)

The drug rucaparib appears active in women with recurrent BRCA-positive ovarian cancer that has progressed after previous treatment. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago,... Continue Reading

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven® (06-11-2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer (06-9-2015)

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American... Continue Reading

Keytruda® Promising in Advanced Head and Neck Cancer (06-8-2015)

The immunotherapy Keytruda® (pembrolizumab) appears active in the treatment of advanced squamous cell head and neck cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer (06-3-2015)

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These... Continue Reading

Next Page »